FHL1 and cardiac hypertrophy: JMJD2A and JMJD3 were reported to regulate cardiac hypertrophy by epigenetically targeting the FHL1 (four-and-a-half LIM domains 1) and the β-MHC promoter, respectively (Zhang et al., 2011; Guo et al., 2018).